Prescient's PTX-100 is targeting a broader range of RAS mutations (KRAS & NRAS) over Amgen's drug solely targeting KRAS G12C.
If our current PTX-100 basket trial headed up by the esteemed & newly appointed SAB member Professor Miles Price continues to demonstrate it's effectiveness, Prescient could very well have the leading RAS inhibitor in the market.
Cheers,
AMS
Prescient's PTX-100 is targeting a broader range of RAS...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $30.60M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.8¢ | $47.91K | 1.256M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 881755 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 150000 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PTX (ASX) Chart |